50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
RPRelx PlcCompany · Professional services · X0 Real “Our purpose is to benefit society by developing products that help researchers advance scientific knowledge; doctors and nurses improve the lives of patients; lawyers promote the rule of law and achieve justice andfair results for their clients; businesses and governments prevent fraud; consumers access financial services and get fair prices on insurance; and customers learn about markets and complete transactions.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-02-1962% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0861% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2860% match
“Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-08-0460% match
“Our mission is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2459% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2459% match
“Our mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2759% match
“Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-10-0759% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1059% match
“Our mission is to deliver significant clinical benefit to patients suffering from disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0459% match
“Our purpose is to operate in accordance with business considerations to generate profits (provided, however, that we may donate reasonable amounts to worthy causes, as our board of directors may determine in its discretion, even if such donations are not within the framework of business considerations).”In use 2010 – now·1 sighting·SEC Form 20-F, filed 2010-03-2659% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0558% match
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1258% match
“Our mission is to bring to market therapies that address high unmet medical needs of patients with genetic mitochondrial diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2758% match
“Our mission is to leverage our existing and expanding network of academic and industry leaders and investors, including venture capital and private equity, in major healthcare markets globally to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-06-1058% match
“Our mission is to discover and develop novel therapeutics to improve the lives of patients living with debilitating CNS disorders.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-10-0658% match
“Our mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0758% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3158% match
“Our mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma.”In use 2016 – now·1 sighting·SEC Form 10-K/A, filed 2016-11-0158% match
“Our mission is to improve the lives of patients suffering from CNS diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0258% match
“Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1058% match
“Our mission is to advance to market novel regenerative medicine and cellular therapy products that substantially benefit humankind.”In use 2016 – now·1 sighting·SEC Form S-1/A, filed 2016-02-0258% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2958% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0157% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1457% match
“Our mission is to improve outcomes for patients living with cancer and genetically defined conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0257% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2957% match
“Our mission is to expand the treatment options for patients who suffer from A fib or have a high risk of stroke through the continued development of our technologies and expansion of our product offerings, global commercial expansion and clinical science investments.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-02-2857% match
“Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0557% match
“Our purpose is to deliver therapies for significant unmet, or under-met, needs to patients, while creating value for our investors.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-1657% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1657% match
“Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune diseases and cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2657% match
“Our purpose is to develop and commercialize HSC gene therapies that free patients from a lifetime of genetic disease.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2357% match
“Our mission is to inspire hope for those battling cancer by expanding on the promise of targeted therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1557% match
“Our mission is to commercialize innovative drug candidates with novel mechanisms of action as well as intellectual property generated from our research activities for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-07-1657% match
“Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2757% match
“Our mission is to partner with our members in Illinois and Wisconsin to provide them competitively priced funding, a reasonable return on their investment in the Bank, and support for their community investment activities.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1057% match
“Our mission is to apply advances in neuroscience and cognitive research to increase human potential.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-3156% match
“Our mission is to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-06-2256% match
“Our mission is to accelerate the discovery, development and global access to targeted radioligand therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2756% match
“Our mission is to discover and develop a pipeline of EPBs to treat a broad range of diseases and disorders, with an initial focus on cancers with a high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-04-2656% match
“Our mission is to make our products and research services available to our clients for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-10-1356% match
“To help customers achieve their financial goals, to deliver a superior return for shareholders, and help to build the economic strength of our communities.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-02-2656% match
“Our mission is to increase shareholder value while providing financial services for and contributing to the growth and welfare of the communities that we serve.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3156% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1156% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1456% match
“Our mission is to bring innovative gene therapy products to patients living with serious, life-threatening rare diseases, and we believe our product candidates have the potential to provide long-lasting and transformative benefits to the patient communities we aim to serve.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0156% match
“Our mission is to develop innovative therapies to address areas of high unmet medical need, initially in RASopathies for NF1.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3056% match
“Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2656% match
“Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2256% match
Showing 1–50 of 50